Skip to main content
Sudeep Pharma Limited logo

Sudeep Pharma Limited — Investor Relations & Filings

Ticker · SUDEEPPHRM ISIN · INE0QPI01025 LEI · 335800ESH1W57DIPAN45 BSE.NS Manufacturing
Open in API
Filings indexed 75 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country IN India
Listing BSE.NS SUDEEPPHRM

About Sudeep Pharma Limited

https://www.sudeeppharma.com/

Sudeep Pharma Limited specializes in the manufacturing of mineral-based excipients and active pharmaceutical ingredients (APIs). The company’s core portfolio includes high-purity mineral salts such as Calcium Phosphates, Calcium Carbonate, and Calcium Sulfate, which are utilized as essential components in solid dosage formulations and nutritional supplements. These products function as diluents, binders, and mineral sources across various applications. The organization maintains advanced production facilities compliant with international quality standards, including GMP, USP, EP, and BP. A strategic partnership with JRS Pharma enhances its technical expertise and global supply chain capabilities. Sudeep Pharma focuses on providing high-quality, regulatory-compliant mineral solutions to meet the demands of global markets, emphasizing research, development, and stringent quality control processes.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of the SEBI (LODR)Regulations, 2015 the Analysts/Investors meet is Scheduled on Friday, 22nd May 2026 at 11:00 a.m. to discuss the operational & financial performance ....
Regulatory Filings Classification · 82% confidence The document is an intimation letter under Regulation 30 of the SEBI Listing Regulations notifying the schedule and registration details for the company’s upcoming earnings call. It contains no financial results, no presentation or transcript content – simply a regulatory notice. This falls under general regulatory announcements, so it should be classified as a Regulatory Filing (RNS).
2026-05-14 English
Sudeep Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Audited Standalone and Consolidated ....
Regulatory Filings Classification · 88% confidence The document is an intimation under Regulation 29 of SEBI LODR notifying a Board meeting date to approve audited financial results and dividend recommendation, along with trading window details. It is a regulatory exchange filing rather than the actual financial report or a notice of dividend, AGM materials or management change. This falls under general regulatory announcements and compliance notices (fallback category).
2026-05-14 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming that no demat requests were received for the quarter ended 31st March 2026. It is addressed to stock exchanges and signed by the company secretary and the registrar and share transfer agent. The document is short (2950 characters) and serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is primarily a regulatory compliance filing confirming shareholding status for a specific quarter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and confirmations.
2026-04-10 English
Submission of Certificate under Regulation 74 (5) of SEBI (DP) Regulations.
Regulatory Filings
2026-04-10 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2026-04-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges regarding the closure of the trading window for insiders in compliance with SEBI (Prohibition of Insider Trading) Regulations. It mentions the upcoming declaration of audited standalone and consolidated financial results for the fiscal year ending March 31, 2026, but does not contain any financial data or the results themselves. The document is short (1983 characters) and serves as an announcement related to insider trading restrictions ahead of financial results disclosure. Therefore, it is not a financial report but a regulatory announcement related to trading restrictions and compliance.
2026-03-26 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.